Description
The marker is associated with the peculiarities of drug metabolism in the liver. It is investigated to identify the physiological effectiveness of the use of drugs: antiplatelet agents (clopidogrel and its analogs), proton pump inhibitors (omeprazole, lansoprazole), antidepressants (amitriptyline), antifungals (voriconazole), psychotropics (diazepam), antitumor drugs (tamoxifen), and others.
Alternative designation of the genetic marker: CYP2C19*2.
Period of execution
Within 6 days. The specified time does not include the day of biomaterial collection
Biomaterial type
- Buccal (cheek) epithelium
- Venous blood